These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; McMurray JJ; Wikstrand J; Aukrust P Am Heart J; 2012 Dec; 164(6):878-83. PubMed ID: 23194488 [TBL] [Abstract][Full Text] [Related]
7. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J; Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888 [TBL] [Abstract][Full Text] [Related]
8. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; Adourian A; Böhm M; van Veldhuisen DJ; Komajda M; Cleland JG; Wikstrand J; McMurray JJ; Aukrust P; Eur Heart J; 2012 Sep; 33(18):2290-6. PubMed ID: 22513778 [TBL] [Abstract][Full Text] [Related]
9. Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). Perez-Moreno AC; Jhund PS; Macdonald MR; Petrie MC; Cleland JG; Böhm M; van Veldhuisen DJ; Gullestad L; Wikstrand J; Kjekshus J; Lewsey JD; McMurray JJ JACC Heart Fail; 2014 Apr; 2(2):187-97. PubMed ID: 24720928 [TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin in older patients with systolic heart failure. Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J; N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166 [TBL] [Abstract][Full Text] [Related]
11. CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. Ueland T; Nymo SH; Latini R; McMurray JJ; Kjekshus J; Yndestad A; Fucili A; Grosu A; Masson S; Maggioni AP; Gullestad L; Aukrust P; ; Eur J Heart Fail; 2013 Jul; 15(7):747-55. PubMed ID: 23487539 [TBL] [Abstract][Full Text] [Related]
12. Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). Perez AC; Jhund PS; Stott DJ; Gullestad L; Cleland JG; van Veldhuisen DJ; Wikstrand J; Kjekshus J; McMurray JJ JACC Heart Fail; 2014 Feb; 2(1):35-40. PubMed ID: 24622117 [TBL] [Abstract][Full Text] [Related]
13. [To treat or not to treat with statins patients with chronic heart failure?]. Hradec J Vnitr Lek; 2009 Sep; 55(9):802-7. PubMed ID: 19785380 [TBL] [Abstract][Full Text] [Related]
14. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). McMurray JJ; Dunselman P; Wedel H; Cleland JG; Lindberg M; Hjalmarson A; Kjekshus J; Waagstein F; Apetrei E; Barrios V; Böhm M; Kamenský G; Komajda M; Mareev V; Wikstrand J; J Am Coll Cardiol; 2010 Oct; 56(15):1196-204. PubMed ID: 20883926 [TBL] [Abstract][Full Text] [Related]
15. Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). Inglis SC; McMurray JJ; Böhm M; Schaufelberger M; van Veldhuisen DJ; Lindberg M; Dunselman P; Hjalmarson A; Kjekshus J; Waagstein F; Wedel H; Wikstrand J; Eur J Heart Fail; 2010 Jul; 12(7):698-705. PubMed ID: 20501489 [TBL] [Abstract][Full Text] [Related]
16. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. Nymo SH; Ueland T; Askevold ET; Flo TH; Kjekshus J; Hulthe J; Wikstrand J; McMurray J; Van Veldhuisen DJ; Gullestad L; Aukrust P; Yndestad A J Intern Med; 2012 May; 271(5):436-43. PubMed ID: 22211640 [TBL] [Abstract][Full Text] [Related]
17. Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Askevold ET; Gullestad L; Nymo S; Kjekshus J; Yndestad A; Latini R; Cleland JG; McMurray JJ; Aukrust P; Ueland T PLoS One; 2015; 10(8):e0133970. PubMed ID: 26288364 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Røysland R; Masson S; Omland T; Milani V; Bjerre M; Flyvbjerg A; Di Tano G; Misuraca G; Maggioni AP; Tognoni G; Tavazzi L; Latini R; Am Heart J; 2010 Aug; 160(2):286-93. PubMed ID: 20691834 [TBL] [Abstract][Full Text] [Related]
19. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Broch K; Ueland T; Nymo SH; Kjekshus J; Hulthe J; Muntendam P; McMurray JJ; Wikstrand J; Cleland JG; Aukrust P; Gullestad L Eur J Heart Fail; 2012 Mar; 14(3):268-77. PubMed ID: 22302661 [TBL] [Abstract][Full Text] [Related]
20. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]